

Eighth EUCAST Steering Committee Meeting

Summary of minutes of meeting held in Munich, Germany, 7-8 September 2004

Attending

Dr Derek F.J. Brown	DB	Scientific Secretary	United Kingdom
Dr Gunnar Kahlmeter	GK	Chairperson	Sweden
Prof Alasdair P. MacGowan	AM	BSAC	United Kingdom
Dr Johan W. Mouton	JM	CRG	The Netherlands
Dr Ingrid Nilsson-Ehle	IN-E	SRGA	Sweden
Prof Arne Rodloff	AR	DIN	Germany
Prof Claude-James Soussy	C-JS	CA-SFM	France
Dr Martin Steinbakk	MS	NWGA	Norway
Dr Olga Stetsiouk	OS	EUCAST	Russia
Dr Francisco Soriano	FS	EUCAST	Spain

Apologies

Dr Anders Österlund	AO	SRGA	Sweden
Dr Fred Goldstein	FG	SFM	France

Attending for daptomycin presentation from Chiron (minute 2)

Jeff Alder	JA	Vice President, Drug Discovery and Evaluation
Paul Derbyshire	PD	Orphix Consulting, Consultant for Chiron
Dave Griffin	DG	Director, Microbiology & Clinical Development Europe
Grace Thorne	GT	Senior Director, Clinical Microbiology

Attending for tigecycline discussion with Wyeth (minute 13)

Dr Patricia Bradford	PB	Associate Director, Discovery Research
Dr Françoise de Cremiers	FC	Vice-President Regulatory Affairs, Europe, Middle East, Africa
Dr Nathalie Dartois	ND	Associate Director, Clinical R&D
Dr Evelyn J. Ellis-Grosse	EE-G	Senior Director, Clinical R&D
Miss Ishwari Kavdikar	IK	Associate Director, Worldwide Regulatory Affairs
Dr Evan Loh	EL	Vice-President, Clinical R&D

1	<p>Chairman's welcome and report Dr Olga Stetsiouk and Dr Francisco Soriano welcomed as new members representing the EUCAST General Committee. IN-E represented SRGA in place of AO, and C-JS represented CA-SFM in place of FG.</p>
2	<p>Daptomycin breakpoints Formal assessment of EUCAST breakpoints for daptomycin was started. Following a presentation by Chiron there was detailed discussion and tentative breakpoints were agreed for discussion by national breakpoint committees.</p>
3	<p>Committee membership 2004/2005 Official terms of GK and DB, and national representatives end in April 2005. GK, DB indicated their willingness to continue but alternatives could be proposed to the ESCMID executive. The national representatives should be confirmed by national committees or replacements named.</p>
4	<p>Minutes of meeting of 30 April 2004 Accepted as a correct record with minor modifications.</p>
5	<p>Matters arising from minutes of 30 April 2004</p> <p>Declarations of interest have been received from almost all Steering Committee members.</p> <p>Table of comments on proposed breakpoints and Steering Committee responses to be updated.</p> <p>Steering Committee expenses claims require evidence of travel.</p> <p>Footnote to glycopeptide breakpoint table modified.</p>

	EUREQAS grant from EU is less than requested. EUCAST contract with EU has been signed.
7	EUCAST documents Intracellular pathogens and mycobacteria documents to be updated.
8	NCCLS GK reported on the June 2004 meeting.
9	CEN/ISO meeting on 17th September 2004 Draft broth microdilution method should be available by the end of the year. First draft of the document on automated system evaluation has been produced. Possibility of a procedure for antifungals was discussed.
10	Collaboration with other groups Collaboration to be pursued with other groups including European Study Group for Sexually Transmitted Infections, a similar group on meningococcal infections and a European Veterinary Group.
11	Letter on EUCAST breakpoint setting procedures and comments on breakpoints from CA-SFM This was discussed in detail and responses agreed. GK and DB to offer to attend a CA-SFM meeting.
12	ECCMID symposium Details of proposed symposium agreed.
13	Presentation on tigecycline by Wyeth There was a preliminary meeting to clarify the requirements of EUCAST before submitting data and requesting breakpoints.
14	EUCAST workshops 2005 Back-to-back meeting with EARSS in November 2005 was proposed. Half day meeting for National Committee members at the ECCMID meeting in Copenhagen agreed.
15	Rationale documents To be developed further.
16	Carbapenem breakpoints Preliminary breakpoints discussed.
17	Any other business None.
18	Next meetings 22-23 November 2004, Madrid 24-25 January 2005, Oslo. 31 March-1 April 2005, Prior to ECCMID 2005, Copenhagen 12-13 September 2005, Munich 21-22 November 2005, venue to be agreed

Minutes ratified 22 November 2004